Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abhinay D Joshi

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
American Journal of Nuclear Medicine and Molecular Imaging|July 20, 2017
Correlation between two methods of florbetapir PET quantitative analysisChristopher Breault, Jonathan Piper, Abhinay D Joshi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2018
Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scaleMichael Navitsky, Abhinay D Joshi, Ian Kennedy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2017
Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18Michael D Devous, Abhinay D Joshi, Michael Navitsky, et al.
BMC Neurology|April 11, 2014
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disordersAndrew Siderowf, Michael J Pontecorvo, Holly A Shill, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2017
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trialsAdam S Fleisher, Abhinay D Joshi, Karen L Sundell, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 22, 2018
Topographic staging of tau positron emission tomography imagesAdam J Schwarz, Sergey Shcherbinin, Lawrence J Slieker, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|May 11, 2016
A Novel Cognitive Stress Test for the Detection of Preclinical Alzheimer Disease: Discriminative Properties and Relation to Amyloid LoadDavid A Loewenstein, Rosie E Curiel, Maria T Greig, et al.
Brain : a Journal of Neurology|January 13, 2017
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognitionMichael J Pontecorvo, Michael D Devous, Michael Navitsky, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2017
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imagingMichael J Pontecorvo, Anupa K Arora, Marybeth Devine, et al.
Archives of Neurology|July 13, 2011
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer diseaseAdam S Fleisher, Kewei Chen, Xiaofen Liu, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Nuclear Medicine and Molecular Imaging|July 20, 2017
Correlation between two methods of florbetapir PET quantitative analysisChristopher Breault, Jonathan Piper, Abhinay D Joshi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2018
Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scaleMichael Navitsky, Abhinay D Joshi, Ian Kennedy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2017
Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18Michael D Devous, Abhinay D Joshi, Michael Navitsky, et al.
BMC Neurology|April 11, 2014
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disordersAndrew Siderowf, Michael J Pontecorvo, Holly A Shill, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2017
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trialsAdam S Fleisher, Abhinay D Joshi, Karen L Sundell, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 22, 2018
Topographic staging of tau positron emission tomography imagesAdam J Schwarz, Sergey Shcherbinin, Lawrence J Slieker, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|May 11, 2016
A Novel Cognitive Stress Test for the Detection of Preclinical Alzheimer Disease: Discriminative Properties and Relation to Amyloid LoadDavid A Loewenstein, Rosie E Curiel, Maria T Greig, et al.
Brain : a Journal of Neurology|January 13, 2017
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognitionMichael J Pontecorvo, Michael D Devous, Michael Navitsky, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2017
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imagingMichael J Pontecorvo, Anupa K Arora, Marybeth Devine, et al.
Archives of Neurology|July 13, 2011
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer diseaseAdam S Fleisher, Kewei Chen, Xiaofen Liu, et al.
Pageof 4